MLTX Insider Purchase: CFO Increases Stake to 627,536 Shares

Rhea-AI Filing Summary

Insider purchase by MoonLake Immunotherapeutics CFO. The filing shows Matthias Bodenstedt, the company’s Chief Financial Officer and a director, purchased 10,870 Class A ordinary shares on 10/08/2025 at a weighted average price of $9.09 per share. After the transactions he beneficially owns 627,536 shares. The filing notes the shares were bought in multiple trades at prices ranging from $9.085 to $9.091244 and that the weighted average price is reported. The signature date is 10/09/2025.

Positive

• CFO purchased 10,870 shares on 10/08/2025 at a weighted average of $9.09, which may indicate executive confidence
• Post-transaction beneficial ownership of 627,536 shares shows substantial insider stake

Negative

• No material negative events disclosed in this Form 4; the filing records only a purchase transaction

Insights

Corporate Governance Analyst

Insider buying by a senior executive can signal confidence in company prospects.

The CFO, Matthias Bodenstedt, acquired 10,870 Class A shares on 10/08/2025 at an average of $9.09, increasing his beneficial holding to 627,536 shares. Insider purchases by officers are often read by investors as alignment with shareholder interests because the buyer is using personal capital.

Dependency and risk hinge on trade size relative to total holdings and any pre-existing trading plan; the form indicates multiple executions with prices between $9.085 and $9.091244. Monitor subsequent Section 16 filings or public disclosures for changes in holding or planned trades within the next quarters.

Insider Trade Summary

Net Buyer: 10,870 shares ($98,808)

Net Buy 1 txn

Insider Bodenstedt Matthias

Role Chief Financial Officer

Bought 10,870 shs ($99K)

Type	Security	Shares	Price	Value
Purchase	Class A ordinary shares, par value $0.0001 per share	10,870	$9.09	$99K

Holdings After Transaction: Class A ordinary shares, par value $0.0001 per share — 627,536 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bodenstedt Matthias

(Last) (First) (Middle)

C/O MOONLAKE IMMUNOTHERAPEUTICS

DORFSTRASSE 29

(Street)

ZUG V8 6300

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MoonLake Immunotherapeutics [ MLTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A ordinary shares, par value $0.0001 per share	10/08/2025		P		10,870	A	$9.09(1)	627,536	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported represents the weighted average purchase price per share. The shares were purchased in multiple transactions at prices ranging from $9.085 to $9.091244. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price.

	/s/ Matthias Bodenstedt	10/09/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did MoonLake Immunotherapeutics (MLTX) CFO buy on 10/08/2025?

The CFO, Matthias Bodenstedt, purchased 10,870 Class A ordinary shares at a weighted average price of $9.09 per share.

How many shares does Matthias Bodenstedt own after the reported transaction?

Following the purchase, he beneficially owns 627,536 Class A ordinary shares.

What price range were the shares bought at in the MLTX Form 4?

The shares were purchased in multiple transactions at prices ranging from $9.085 to $9.091244; the filing reports a weighted average of $9.09.

When was the Form 4 signed and filed for the MLTX transaction?

The Form 4 bears a signature date of 10/09/2025 and reports the earliest transaction date as 10/08/2025.

Does the Form 4 disclose any derivative transactions or disposals?

No. Table II for derivatives shows no reported transactions; Table I records only the non-derivative purchase of Class A ordinary shares.